PI3K/Akt/CREB activator 1

SKU: orb1745043

Description

AE-18 is a selective iNOS inhibitor that crosses the blood-brain barrier. It has demonstrated neuroprotective effects in rat models of ischemia-reperfusion, reducing infarct size and improving cerebral blood flow. This compound is utilized in research areas such as vascular dementia and Parkinson's disease.

Research Area

Epigenetics & Chromatin, Signal Transduction, Stem Cell & Developmental Biology

Key Properties

• CAS Number: 2708177-73-3
• MW: 381.32
• Formula: C₁₉H₁₅F₄NO₃
• SMILES: C([C@H](NC(/C=C/C1=CC=C(C(F)(F)F)C=C1)=O)C(O)=O)C2=CC=C(F)C=C2
• Target: PI3K|||Epigenetic Reader Domain|||Akt
• Solubility: DMSO:200 mg/mL (524.49 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:5 mg/mL (13.11 mM)

Bioactivity

• In Vivo:
  In male Sprague-Dawley rats in a chronic cerebral hypoperfusion (CCH) model, gavage of 5 and 10 mg/kg PI3K/Akt/CREB activator 1 promoted the recovery of cerebral blood flow (CBF) after bilateral common carotid artery ligation (BCCAO). PI3K/Akt/CREB activator 1 (5 and 10 mg/kg; by gavage; for 5 consecutive days) attenuated learning and memory impairments in a rat model of CCH, while alleviating hippocampal pathology damage caused by BCCAO.
  Read more...
• In Vitro:
  PI3K/Akt/CREB activator 1 (Compound AE-18) (10 and 20 μM; 48 hr treatment) enhances BDNF expression in Neuro-2a cells through activation of the PI3K/Akt/CREB pathway, which promotes the formation of neurites and cell proliferation. Treatment of neurons with 10 and 20 μM PI3K/Akt/CREB activator 1 enhances the differentiation of cultured hippocampal neurons and promotes axonal and dendritic polarity formation through the PI3K/Akt signaling pathway.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Compound Identifiers

PubChem CID

165437247